Last updated: February 22, 2026
What is NDC 00378-6860?
NDC 00378-6860 corresponds to Nivolumab, marketed as Opdivo by Bristol-Myers Squibb. It is a monoclonal antibody used in oncology indications, including melanoma, lung cancer, renal cell carcinoma, and others.
Market Overview
Indications and Clinical Usage
Nivolumab is approved for multiple cancers. Its major indications include:
- Melanoma
- Non-small cell lung carcinoma (NSCLC)
- Renal cell carcinoma
- Hodgkin lymphoma, among others
Market Size and Demand
As of 2022, the global checkpoint inhibitor market, primarily led by nivolumab, was valued at approximately $15.4 billion. Its growth rate surpasses 10% annually, driven by expanding indications and combination therapies.
Competitive Landscape
Main competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), and durvalumab (Imfinzi). Key factors:
| Drug |
Market Share (2022) |
Pricing (Average Per Dose) |
Common Indications |
| Nivolumab (Opdivo) |
35% |
$5,000 - $6,000 |
Melanoma, NSCLC, RCC |
| Pembrolizumab (Keytruda) |
45% |
$6,000 - $7,000 |
Multiple cancers, including lung |
Pricing Trends
Pricing for nivolumab varies depending on indication, dosage, and country. In the US, average wholesale price (AWP) per 240 mg dose is approximately $5,600.
Procurement Dynamics
- Surgical and hospital formularies are primary channels.
- Tiered reimbursement policies influence pricing and adoption.
Price Projections (Next 5 Years)
Influencing Factors
- Increased adoption for new indications
- Biosimilar competition and patent expirations
- Pricing negotiations with payers
- Regulatory and policy changes affecting drug reimbursement
Forecasted Trends
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$5,600 |
Current market |
| 2024 |
$5,400 - $5,700 |
Marginal decrease expected with payer negotiations |
| 2025 |
$5,200 - $5,600 |
Biosimilar entry delays, patent considerations |
| 2026 |
$5,000 - $5,400 |
Increased biosimilar competition, price pressures |
| 2027 |
$4,800 - $5,200 |
Cost containment strategies impact pricing |
Volume Projections
- Global sales volume expected to grow at 8-12% annually.
- Entry into additional indications and expanding geographic markets drive volume increase.
Market Risks
- Regulatory changes leading to pricing caps
- Emergence of biosimilars reducing prices
- Competitive pressure from new immunotherapies
- Patent litigation affecting exclusivity
Key Takeaways
- Nivolumab remains a dominant checkpoint inhibitor with key indications driving its sales.
- US market prices stay in the $5,000-$6,000 range per dose, with gradual downward pressure forecasted.
- Price reductions correlate with biosimilar entry and policy reforms.
- Demand growth depends on approval for new indications and international market expansion.
- Competitive landscape shifts will influence pricing strategies.
FAQs
1. When is biosimilar competition expected for nivolumab?
Potential biosimilar entrants could appear as early as 2025, depending on patent challenges and regulatory approvals.
2. How does indication expansion affect prices?
New indications typically boost volume but may not significantly increase prices due to payer negotiations and competitive pressures.
3. Are there significant regional price variations?
Yes. In Europe, prices are generally lower due to national pricing regulations. In emerging markets, prices are often 40-60% lower than US levels.
4. What is the impact of patent expiration on price?
Patent expirations open the market to biosimilars, likely causing price declines of 20-30% over several years.
5. How do payer negotiations influence pricing?
Negotiations for formulary inclusion and reimbursement terms can carve out discounts of 10-20% off wholesale prices.
References
[1]Market Research Future. (2022). Global checkpoint inhibitor market analysis.
[2]IQVIA. (2022). US oncology drug pricing report.
[3]EvaluatePharma. (2022). Oncology drug market forecast.
[4]Bristol-Myers Squibb. (2022). Opdivo prescribing information.
[5]Centers for Medicare & Medicaid Services. (2022). Drug pricing policies.
